A Phase 1 interventional study of Cilofexor in Nonalcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC), sponsored by Gilead Sciences. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 16th largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 1, and was the 7th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is close to the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
Key Inclusion Criteria:
Cohort 1:
Cohort 2:
Cohort 3:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
Drug: Cilofexor
Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
Drug: Cilofexor
Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
Drug: Cilofexor
Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
Drug: Cilofexor
Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
Drug: Cilofexor
Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
Drug: Cilofexor
Tablet(s) administered orally in a fed state on Day 1
Also known as: GS-9674
Pharmacokinetic (PK) Parameter: AUClast of Cilofexor
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: AUCinf of Cilofexor
AUCinf is defined as the concentration of drug extrapolated to infinite time.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: Cmax of Cilofexor
Cmax is defined as the maximum concentration of drug.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: %AUCexp of Cilofexor
%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: Clast of Cilofexor
Clast is defined as the last observable concentration of drug.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: Tmax of Cilofexor
Tmax is defined as the time (observed time point) of Cmax.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: Tlast of Cilofexor
Tlast is defined as the time (observed time point) of Clast.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: λz of Cilofexor
λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: CL/F of Cilofexor
CL/F is defined as the apparent oral clearance following administration of the drug.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: Vz/F of Cilofexor
Vz/F is defined as the apparent volume of distribution of the drug.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
PK Parameter: t1/2 of Cilofexor
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame: Day 1 up to Day 31
Percentage of Participants Who Experienced Graded Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose at any time postdose up to and including the date of last study drug dose plus 30 days. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Day 1 up to Day 31
Pharmacodynamic (PD) Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for α-hydroxy-4-cholesten-3-one (C4)
AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
PD Parameter: Mean Day 1/ Day -1 Ratio of Cmin for α-hydroxy-4-cholesten-3-one (C4)
Cmin for C4 is defined as the minimum observed concentration of C4. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
PD Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for Fibroblast Growth Factor 19 (FGF19)
AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
PD Parameter: Mean Day 1/ Day -1 Ratio of Cmax for Fibroblast Growth Factor 19 (FGF19)
Cmax for FGF19 is defined as the maximum observed concentration of FGF19. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
Participants were enrolled at study sites in the United States (US) and New Zealand. The first participant was screened on 13 July 2016. The last study visit occurred on 16 October 2018.
| Milestone | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 & 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|
| Started | 10 | 10 | 17 | 10 | 10 |
| Completed | 10 | 10 | 16 | 10 | 10 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Enrolled but never treated | 0 | 0 | 1 | 0 | 0 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| h*ng/mL | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter: AUClast of Cilofexor | 5381.0 ± 2175.34 | 2972.6 ± 1230.49 | 8223.7 ± 7492.41 | 2756.7 ± 851.38 | 6534.3 ± 3791.05 | 960.0 ± 352.71 |
AUCinf is defined as the concentration of drug extrapolated to infinite time.
| h*ng/mL | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: AUCinf of Cilofexor | 5411.9 ± 2181.82 | 3024.3 ± 1224.02 | 8288.2 ± 7583.42 | 2805.6 ± 851.26 | 6719.4 ± 4056.73 | 986.2 ± 354.93 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: Cmax of Cilofexor | 994.1 ± 533.38 | 603.5 ± 275.33 | 909.2 ± 477.20 | 495.7 ± 199.45 | 426.6 ± 136.40 | 182.4 ± 86.67 |
%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.
| percentage of AUCexp | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: %AUCexp of Cilofexor | 0.63 ± 0.270 | 1.95 ± 1.621 | 0.64 ± 0.194 | 1.87 ± 1.653 | 1.81 ± 1.874 | 2.96 ± 1.962 |
Clast is defined as the last observable concentration of drug.
| ng/mL | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: Clast of Cilofexor | 1.97 ± 1.005 | 3.84 ± 2.162 | 2.76 ± 3.377 | 3.73 ± 2.378 | 6.03 ± 8.044 | 2.18 ± 1.387 |
Tmax is defined as the time (observed time point) of Cmax.
| hours | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: Tmax of Cilofexor | 3.75 (2.50 to 5.00) | 3.00 (2.50 to 4.00) | 4.50 (2.50 to 10.00) | 3.75 (2.50 to 4.00) | 5.00 (5.00 to 6.00) | 4.00 (3.00 to 5.00) |
Tlast is defined as the time (observed time point) of Clast.
| hours | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: Tlast of Cilofexor | 64.80 (48.00 to 72.02) | 48.00 (24.00 to 72.00) | 72.00 (72.00 to 96.00) | 48.00 (24.00 to 72.00) | 96.00 (96.00 to 96.00) | 48.00 (24.00 to 48.00) |
λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
| 1/hour | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: λz of Cilofexor | 0.070 ± 0.0377 | 0.099 ± 0.0661 | 0.051 ± 0.0152 | 0.100 ± 0.0655 | 0.045 ± 0.0117 | 0.099 ± 0.0659 |
CL/F is defined as the apparent oral clearance following administration of the drug.
| mL/h | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: CL/F of Cilofexor | 6621.5 ± 3219.50 | 11324.4 ± 4184.32 | 5264.4 ± 2686.26 | 11631.7 ± 3666.25 | 1963.1 ± 964.19 | 11535.9 ± 4627.39 |
Vz/F is defined as the apparent volume of distribution of the drug.
| mL | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: Vz/F of Cilofexor | 97797.6 ± 18500.74 | 148898.5 ± 81520.19 | 99541.7 ± 31192.41 | 153854.9 ± 83844.37 | 41375.1 ± 11767.71 | 160423.9 ± 92259.03 |
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| hours | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PK Parameter: t1/2 of Cilofexor | 11.45 (8.50 to 12.94) | 9.49 (4.78 to 11.67) | 13.53 (11.56 to 18.15) | 8.12 (4.90 to 15.02) | 15.90 (12.85 to 19.02) | 9.31 (5.15 to 11.61) |
| percentage of participants | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 and 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 10.0 | 20.0 | 12.5 | 30.0 | 0 |
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose at any time postdose up to and including the date of last study drug dose plus 30 days. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 and 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|
| Any Laboratory Abnormality | 90.0 | 100.0 | 50.0 | 100.0 | 60.0 |
| Grade 3 or above Laboratory Abnormalities | 20.0 | 20.0 | 0 | 40.0 | 0 |
AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
| ratio | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| Pharmacodynamic (PD) Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for α-hydroxy-4-cholesten-3-one (C4) | 0.706 ± 0.2273 | 0.817 ± 0.2836 | 0.716 ± 0.2370 | 0.681 ± 0.2614 | 1.063 ± 0.2469 | 0.978 ± 0.4155 |
Cmin for C4 is defined as the minimum observed concentration of C4. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
| ratio | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PD Parameter: Mean Day 1/ Day -1 Ratio of Cmin for α-hydroxy-4-cholesten-3-one (C4) | 0.599 ± 0.3272 | 0.707 ± 0.2838 | 0.668 ± 0.2384 | 0.583 ± 0.1634 | 0.953 ± 0.2073 | 0.727 ± 0.2674 |
AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
| ratio | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PD Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for Fibroblast Growth Factor 19 (FGF19) | 3.031 ± 1.0376 | 2.840 ± 0.9254 | 3.730 ± 1.3768 | 2.848 ± 1.0250 | 1.582 ± 0.8182 | 2.179 ± 1.6972 |
Cmax for FGF19 is defined as the maximum observed concentration of FGF19. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.
| ratio | Cohort 1: Mild Hepatic Impairment | Cohort 1: Normal Hepatic Function | Cohort 2: Moderate Hepatic Impairment | Cohort 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|---|
| PD Parameter: Mean Day 1/ Day -1 Ratio of Cmax for Fibroblast Growth Factor 19 (FGF19) | 3.778 ± 1.4954 | 3.494 ± 1.4423 | 4.459 ± 1.9899 | 3.145 ± 1.4484 | 1.899 ± 1.1619 | 2.098 ± 1.1579 |
Collected over Day 1 up to Day 31. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Mild Hepatic Impairment | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Cohort 2: Moderate Hepatic Impairment | 0/10 (0%) | 1/10 (10%) | 1/10 (10%) |
| Cohort 1 and 2: Normal Hepatic Function | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Cohort 3: Severe Hepatic Impairment | 0/10 (0%) | 1/10 (10%) | 2/10 (20%) |
| Cohort 3: Normal Hepatic Function | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Event | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 and 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/10 | 1/10 | 0/16 | 0/10 | 0/10 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/10 | 0/10 | 0/16 | 1/10 | 0/10 |
| Event | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 and 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function |
|---|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/10 | 1/10 | 0/16 | 0/10 | 0/10 |
| Skin abrasionInjury, poisoning and procedural complications | 0/10 | 0/10 | 0/16 | 1/10 | 0/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/10 | 0/10 | 0/16 | 1/10 | 0/10 |
| HaematomaVascular disorders | 1/10 | 0/10 | 0/16 | 0/10 | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 0/10 | 1/16 | 0/10 | 0/10 |
| HeadacheNervous system disorders | 0/10 | 0/10 | 1/16 | 0/10 | 0/10 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 & 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function | Total |
|---|---|---|---|---|---|---|
| Mean | 54 ± 10.1 | 57 ± 8.9 | 55 ± 7.6 | 54 ± 9.5 | 52 ± 8.4 | 54.45 ± 8.67 |
| Sex: Female, Male(Participants) | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 & 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 5 | 3 | 3 | 16 |
| Male | 7 | 8 | 11 | 7 | 7 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 & 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 7 | 6 | 5 | 25 |
| Not Hispanic or Latino | 6 | 7 | 9 | 4 | 5 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 & 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 | 1 | 3 |
| White | 8 | 10 | 15 | 9 | 9 | 51 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1: Mild Hepatic Impairment | Cohort 2: Moderate Hepatic Impairment | Cohort 1 & 2: Normal Hepatic Function | Cohort 3: Severe Hepatic Impairment | Cohort 3: Normal Hepatic Function | Total |
|---|---|---|---|---|---|---|
| New Zealand | 2 | 1 | 3 | 1 | 1 | 8 |
| United States | 8 | 9 | 13 | 9 | 9 | 48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Oct 2018, 27 months.
Results were first posted in Sep 2020, 1 year 11 months after primary completion.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 27 months is above that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor
Non-alcoholic Fatty Liver Disease →